Strattera (atomoxetine hydrochloride) capsules
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011
- Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received STRATTERA. Therefore, STRATTERA should not be taken by patients with pheochromocytoma or a history of pheochromocytoma.
- addition of similar statement regarding pheochromocytoma